Loss-of-function mutations in the FLG (filaggrin) gene cause the semidominant keratinizing disorder ichthyosis vulgaris 1 and convey major genetic risk for atopic dermatitis (eczema) [2] [3] [4] , eczema-associated asthma 2,3 and other allergic phenotypes 5 . Several low-frequency FLG null alleles occur in Europeans and Asians, with a cumulative frequency of B9% in Europe 4 . Here we report a 1-bp deletion mutation, 5303delA, analogous to common human FLG mutations, within the murine Flg gene in the spontaneous mouse mutant flaky tail (ft). We demonstrate that topical application of allergen to mice homozygous for this mutation results in cutaneous inflammatory infiltrates and enhanced cutaneous allergen priming with development of allergen-specific antibody responses. These data validate flaky tail as a useful model of filaggrin deficiency and provide experimental evidence for the hypothesis that antigen transfer through a defective epidermal barrier is a key mechanism underlying elevated IgE sensitization and initiation of cutaneous inflammation in humans with filaggrin-related atopic disease.
Eczema is a common disease affecting 15-30% of children and 2-10% of adults in developed countries 6 . There is a strong genetic association with atopic disorders including asthma, hay fever and food allergy 7 . Elevated total IgE is observed in 60-80% of individuals with eczema attending secondary care. Although IgE sensitization increases in the first few years of life in children with eczema 8 , the timing and pathogenic role of IgE sensitization in the development of atopic dermatitis remains uncertain 9 . Recent evidence strongly suggests that children with early-onset (o3 months) and more severe eczema have the greatest risk of IgE sensitization. Although debate remains as to the relative contributions of inherited barrier defects versus immunological aberrations, the major genetic risk identified to date is associated with loss-of-function mutations in FLG, encoding the skin barrier protein profilaggrin/filaggrin 2, 4 .
The spontaneous recessive mouse mutant flaky tail (ft) arose in 1958 on the background of an existing recessive hair phenotype, matted (ma), and since then has been maintained on a mixed strain 10 . Flaky tail mice have dry, flaky skin and annular tail and paw constrictions in the neonatal period 11 . Protein blot analysis shows that ft/ft mice express a truncated profilaggrin (B215 kDa) instead of the normal high-molecular-weight profilaggrin (4500 kDa) 11 . Although processed filaggrin in these mice has been shown to be virtually absent at the protein level 11 , the underlying genetic mechanism is unknown. Given the likely genetic similarity between flaky tail mice and human ichthyosis vulgaris and atopic eczema, we sought to identify the genetic mechanism underlying this mutant and study in detail the function of the skin barrier in ft/ft mice with respect to ease of allergen priming.
The mouse filaggrin gene, Flg, is located on chromosome band 3QF2.1 within a cluster of seven genes encoding the fused S100 family of filaggrin-like proteins (Fig. 1) . The organization of this cluster is identical to the orthologous human cluster. We manually annotated the intron-exon organization of the 20,150-bp Flg gene from the current build of the C57BL/6 mouse genome ( Fig. 1a and Supplementary Table 1 online). The genomic sequence derived from BAC clone RP23-227A12 contains small assembly errors owing to incomplete resolution of the tandem repeats within Flg. We resolved this issue by aligning individual filaggrin repeats and correcting the five detected assembly errors (Supplementary Table 2 online) so that the complete ORF was in-frame with the reported short partial 5¢ and 3¢ cDNA sequences for mouse Flg 12, 13 . The predicted 496-kDa mouse profilaggrin consists of 4,654 amino acids, including 16 full near-identical repeats of a 250-amino-acid filaggrin consensus sequence (repeats 1-16), flanked by two incomplete repeats (repeats 0 and 17; Fig. 1a ). Most repeats are less than 1% different in protein sequence from each another. The amino terminus consists of a conserved S100 calcium-binding domain 14 and a B-domain postulated to have a signaling function 12, 15 . The domain organization is identical to that of human profilaggrin 4 , except that the mouse protein has 16 repeats of a smaller 250-amino-acid sequence versus 10-12 repeats of 324 amino acids in humans 4 . The number of repeats has been shown to vary among mouse strains 16 , as it does in the human population 4, 17 . Downstream of repeat 17 is a unique C-terminal domain. A polyclonal antibody raised against a synthetic peptide derived from the C-terminal tail domain recognized full-length B500-kDa profilaggrin in wild-type mice, as well as intermediates from profilaggrin-to-filaggrin processing ( Fig. 2) , validating the predicted amino-acid sequence. Although traces of truncated profilaggrin (B215 kDa) can be seen in ft/ft homozygotes by total protein staining ( Fig. 2a ) and in protein blots using antibodies against a filaggrin repeat epitope, as previously reported 11 , they are not recognized by the C-terminal antibody, predicting a truncating mutation ( Fig. 2b) .
Long-range PCR methods used to identify human FLG mutations 1,4 proved unable to amplify the larger exon 3 of mouse Flg. We therefore Figure 1 Flg gene structure and mutation identification. (a) Flg resides within a cluster of seven genes encoding closely related fused-S100 proteins, spanning B350 kb on chromosomal band 3QF21. Like human FLG, mouse Flg has three exons. Exon 1 consists of 5¢-UTR sequences only; exon 2 contains the ATG and encodes part of the N-terminal S100 calciumbinding domain of profilaggrin; and exon 3 encodes the remainder of the S100 domain, the B-domain and the filaggrin polyprotein repeat domain. In the July 2007 mouse genome sequence annotated here (Flg C57 ), the latter consists of 16 near-perfect repeats encoding a 250-amino-acid filaggrin protein (1-16) flanked by two imperfect repeats (0 and 17). Repeat 17 is followed by a short tail domain. In ft mice, the exon 3 sequence (Flg ft ) lacks one repeat owing to a 750-bp in-frame deletion, as well as the frameshift mutation 5303delA. There are also several additional SNPs and small in-frame insertions/deletions in Flg that differ between the two strains; their DNA sequences overall are 99.3% identical, excluding the repeat copy number variation. The antibody detects both full-length profilaggrin (P) and a putative C-terminal processing product (C) in wild-type mouse extracts; however, these immunoreactive products are not detected in ft/ft mice (b). Note the lack of filaggrin (F) in ft/ft mice (a), as observed previously 11 . The mutant profilaggrin protein in ft/ft mice is faintly visible in a at an apparent molecular weight of B215 kDa (*). This is readily detectable with a mouse filaggrin antibody as reported previously 11 . Molecular weight marker sizes are shown at left.
used a shotgun sequencing method whereby six species of short PCR fragments were generated and cloned using primers designed to amplify any of the repeat units, as recently used to detect human FLG mutations 18 . By sequencing 4900 clones, we detected a 1-bp deletion in clones resulting from four different PCR fragments ( Fig. 1b,c) . Allele-specific PCR genotyping showed that this deletion completely cosegregated with the ft phenotype in many mouse crosses ( Fig. 1d ). We also detected an AccI restriction fragment length polymorphism in filaggrin repeat 1 in tight linkage with the mutation. This marker proved to be convenient for genotyping ft mice, as heterozygotes are more easily scored than by allele-specific PCR (Fig. 1e ). The ft mutation was subsequently backcrossed and maintained in our laboratories on the C57BL/6 background. Early in the course of backcrossing, we were able to remove the matted hair allele (ma) originally present on this mixed strain. Given the nature of the shotgun method initially used, it was not possible to assemble the complete ft sequence for exon 3. However, we constructed a BAC library from an ft/ft homozygote and isolated a clone containing the entire Flg locus. We then subcloned exon 3 by recombineering and oversequenced by Bninefold the resultant plasmid by random transposon insertion methodology. We sequenced exons 1 and 2 from ft/ft mice by standard PCR methods, allowing full assembly of the Flg sequence from the mutant strain. By this means, the mutation was unambiguously designated as 5303delA in filaggrin repeat 6, leading to premature termination 154 codons downstream (Asn1768ThrfsX154). The Flg sequence from ft mice was one filaggrin repeat shorter than the C57BL/6 sequence, consistent with earlier studies reporting variation in filaggrin repeat copy number both in mice and humans 4, 17 . Otherwise, the coding sequence showed 99.3% identity between C57BL/6 and ft, with no other loss-of-function variants detected. Partial sequencing of Flg in different mouse strains suggested that the Flg locus in ft was originally derived from the C3H strain (data not shown).
We took skin biopsies for histopathological analysis from 6-to 8-week-old age-and sex-matched wt/wt (wild-type), wt/ft (heterozygous) and ft/ft (homozygous) mice. No overt differences were noted between wt/wt and wt/ft (Fig. 3a) . In contrast, ft/ft mice had a mild diffuse orthokeratotic hyperkeratosis (a hypertrophy of the stratum corneum of the skin characterized by the presence of non-nucleated cells). We also observed occasional foci of acanthosis (abnormal thickening of the stratum spinosum layer of the skin), which varied in magnitude among individual ft/ft mice ( Fig. 3a) . In our hands, ft/ft mice have a phenotype consistent with the original description 11 but do not have significant acanthosis or alterations to the stratum granulosum as previously reported 11 possibly because histopathological analysis was done at a younger age. We observed a broad spectrum of severity of skin pathologies among individual ft/ft mice, including some with sporadic superficial dermal cellular infiltrates. We further characterized the cutaneous cellular infiltrate and, according to the number of cells detected per field (Â1,000), we observed significantly more total cells (P o 0.05), lymphocytes (P o 0.01), eosinophils (P o 0.05) and mononuclear cells (P o 0.01) in ft/ft relative to wt/wt and wt/ft mice (Fig. 3b) . To address the baseline integrity of the skin barrier of ft animals, we measured transepidermal water loss (TEWL) on the skin of adult age-matched wt/wt, wt/ft and ft/ft mice. Although there were higher individual TEWL readings in ft/ft mice, possibly reflecting the spectrum of severity in skin inflammation within this group, there was no statistically significant difference in baseline TEWL among the three groups ( Fig. 3c) .
To test allergen priming of the skin in these mice, we used the widely studied and clinically relevant allergen ovalbumin (OVA). We applied OVA or PBS (as a vehicle control) to the shaved abdominal skin of wt/wt, wt/ft and ft/ft mice (for full protocol, see Supplementary Fig. 1a online) . Cutaneous exposure to OVA did not lead to gross skin lesions in any mice (data not shown). Skin removed from the site of allergen challenge showed evidence of some edema and a nonsignificant increase in cellular infiltrates but no gross damage or inflammation in wt/wt or ft/wt mice ( Fig. 4a,b) . In contrast, exposure of OVA to the skin of ft/ft mice induced diffuse mild acanthosis, with significant infiltrates of mixed, predominantly lymphocytic inflammatory cells, in addition to eosinophils and mononuclear cells ( Fig. 4a,b ). Measurement of TEWL at the site of allergen challenge 24 h after OVA application revealed a significant (P o 0.0001) elevation in TEWL of OVA-treated ft/ft mice relative to PBS-treated ft/ft and wt/wt and wt/ft mice ( Fig. 4c ). Application of OVA to wt/wt or wt/ft mice caused no alteration in TEWL ( Fig. 4c) .
We then analyzed the systemic immune response to OVA. Following cutaneous allergen exposure, wt/wt mice did not have elevated levels of total serum IgE, nor did they generate an antibody (IgG or IgE) response to OVA ( Fig. 5a and Supplementary Fig. 2 online) , and spleen cells from wt/wt mice did not proliferate or produce cytokines when exposed to OVA in vitro (Fig. 5b,c) . In contrast, percutaneous allergen exposure in ft/ft mice generated OVA-specific IgG and OVA-specific IgE that was significantly (P 4 0.005) elevated relative to other PBS-or OVA-treated groups (Fig. 5a ). The absence of allergen-specific responses in wt/wt mice upon allergen-challenge to intact skin has been reported previously in the background strain of the ft/ft mice used here (C57BL/6) 19 ; however, an allergic response can be generated when OVA is applied after the skin barrier has been disrupted by tape-stripping 20 . Spleen cells from OVA-exposed ft/ft mice proliferated in a dose-dependent manner in response to OVA, whereas cells from other test groups did not proliferate ( Fig. 5b) .
None of the PBS-treated groups developed OVA-specific cytokine responses in splenic cells (data not shown). Spleen cells from OVAtreated wt/wt and wt/ft mice did not secrete cytokines in response to OVA (Fig. 5c) . In contrast, ft/ft mice produced OVA-specific Th2 (IL-4, IL-5, IL-13), Th1 (IFN-g), regulatory (IL-10) and Th17 (IL-17) cytokines (Fig. 5c) , indicating a generalized allergen-specific cytokine response that was not solely Th2 skewed. Consistent with a mixed T helper cytokine response in ft/ft mice treated with OVA cutaneously, there was elevation of serum levels of both OVA-specific IgG2a and IgG1, antibody isotypes that are induced by Th1 and Th2 cytokines, respectively 21 ( Supplementary Fig. 2b ). In these studies, wt/ft animals were comparable to wt/wt mice with respect to all parameters analyzed ( Figs. 3-5 ).
These data show that ft/ft mice generate allergen-specific IgE and cytokine responses following cutaneous allergen challenge to intact skin. Several large studies have shown that FLG loss-of-function mutations predispose to asthma in the context of atopic dermatitis 5, [22] [23] [24] . To experimentally address this association using the mouse model, we treated ft/ft and wt/wt animals that had been percutaneously treated with OVA with OVA aerosol to evoke pulmonary sensitization and airway hyper-responsiveness (AHR), and analyzed pulmonary responses ( Supplementary Fig. 1b ). AHR, determined as airway resistance (R L ), was not induced in OVA-exposed ft/ft or wt/wt mice, with both OVA-exposed groups having similar R L values as PBS-exposed mice ( Supplementary Figs. 3 and 4 online). No airway inflammation was seen on lung histology sections from wt/wt or ft/ft mice exposed to OVA via the skin (Supplementary Fig. 5a online) , which was subsequently confirmed and quantified by scoring histology sections (data not shown). Furthermore, there was no significant elevation in the numbers of total cells and eosinophils recovered in bronchoalveolar lavage (BAL) fluid between OVA-exposed or PBS-treated ft/ft and wt/wt mice ( Supplementary Fig. 5c,d) . OVA application to barrierdisrupted skin of wt/wt mice, as used to induce AHR on the more Th2 immunoreactive BALB/c strain previously 25 , also failed to induce AHR in tape-stripped C57BL/6 mice ( Supplementary Fig. 4a ). The inability to induce AHR after cutaneous OVA challenge may thus reflect the use of C57BL/6 mice, which are less susceptible than BALB/c mice to allergen-induced Th2 inflammation.
To confirm that the OVA sensitization shown here in ft/ft is due to a specific defect in the skin barrier rather than a generalized altered immunity, we gave intraperitoneal injections of OVA and adjuvant (Alum) to ft/ft and wt/wt mice. We then evaluated allergen-specific responses ( Supplementary Fig. 3b online) . ft/ft mice intraperitoneally immunized with OVA and adjuvant developed allergen-specific immune responses comparable to wt/wt animals, with both groups developing a Th2-biased OVA-specific cytokine and antibody isotype response ( Supplementary Fig. 6 online) .
To address whether the lack of pulmonary inflammation in ft/ft mice following allergen challenge was due to altered lung immunity and development of AHR in ft/ft mice, we challenged these animals and wt/wt mice intraperitoneally with OVA and adjuvant followed by pulmonary allergen sensitization ( Supplementary Fig. 3a ). There was comparable induction of AHR, determined as lung resistance (R L ), in wt/wt and ft/ft mice ( Supplementary Fig. 7 online) . Furthermore, intraperitoneal challenge with OVA and adjuvant resulted in airway inflammation in both wt/wt and ft/ft mice ( Supplementary Fig. 5b) , with no differences between groups in the magnitude of lung inflammation detected (data not shown). Therefore ft/ft mice develop allergic lung inflammation after intraperitoneal priming with OVA and adjuvant but not when sensitized via the skin to OVA in the absence of adjuvant. Further work is needed to dissect whether this is due to the type of OVA-specific response generated in the absence of Alum, a Th2-inducing adjuvant, as opposed to the response generated following skin exposure to allergen in the absence of adjuvant.
Here we have identified the flaky tail mutation as a frameshift mutation 5303delA in repeat 6 of Flg (Fig. 1) . Several truncating mutations have been reported in human FLG 4 , including three in repeat 6. Notably, the truncated profilaggrin species resulting from mutations in repeats 7 and 10 of FLG have been shown to be highly unstable and incapable of being processed to functional filaggrin 4 , as shown in the ft mouse here (Fig. 2) and previously 11 . Thus, the 5303delA mutation is a null allele, analogous to many of the human FLG mutations now emerging, and might be a better model for the human mutations than a knockout allele, which has proven difficult to generate owing to the repetitive nature of this locus (R.B.P. and W.H.I.M., unpublished data). Availability of genotyping assays for the mutant allele will allow generation of congenic strains and double mutant mice to further dissect the immunological and biological effects of Flg mutations.
Although ft/ft mice closely model the phenotypic, histological and ultrastructural characteristics of ichthyosis vulgaris in humans 11 , we show here that these filaggrin-deficient mice are also predisposed to develop sensitization following percutaneous exposure to a model allergen, and develop cutaneous inflammatory infiltrates and allergenspecific immune responses following allergen sensitization (Fig. 5) . Following sensitization, a further skin barrier defect, as measured by elevated TEWL, is seen, suggesting that the mild initial heritable barrier defect is exacerbated by allergic sensitization. This suggests that sensitization might also be an early event in filaggrin-deficient humans. Several known modifiers (for example, Th2 cytokines, including IL-13 and IL-4) have been shown to downregulate expression of filaggrin 26 and other key epidermal structural proteins 27 , and unknown genetic factors may also influence the phenotype of ft/ft mice; these areas require further experimentation. It is noteworthy that PBS-treated ft/ft mice showed no elevation of total IgE up to 12-13 weeks of age ( Fig. 5) . Indeed, in 8-month-old untreated ft/ft mice, we have observed no increase in nonspecific IgE or elevated Th2 cytokine (IL-4, IL-5 and IL-13) production, and there are no previous reports of spontaneous atopy or eczema in ft/ft mice 10, 11 . Thus, ft/ft mice maintained under specific pathogen-free conditions do not appear to develop spontaneous allergic responses, in contrast to NC/Nga mice 28 .
As noted above, the role of elevated IgE in human atopic dermatitis remains unresolved. Given a recent report of a mouse model of intrinsic atopic eczema 29 , which highlights the potential for eczema in mice in the absence of elevated IgE, caution is needed in assigning an obligate pathogenic role for elevated IgE in mouse atopic dermatitis. Although clarifying this relationship will require more experimentation on mouse models in addition to human studies, we have shown enhanced percutaneous priming in a mouse model of filaggrin deficiency that hints at possible mechanisms in the human disease. These findings set the scene for the use and further refinement of this animal model to further dissect the role of filaggrin in skin barrier function and the genesis of atopic eczema.
METHODS
Sequence analysis. We annotated the genomic sequence of the mouse Flg locus derived from BAC clone RP23-227A12 using the ClustalW tools within MacVector version 9.0. To identify the causative mutation in ft/ft mice, we applied the shotgun method recently developed to identify FLG mutations in humans with atopic dermatitis 18 . We used six pairs of PCR primers based on Flg exon 3 sequence on BAC clone RP23-227A12, designed to amplify each filaggrin homologous sequence unit (Supplementary Table 3 online). The PCR products were cloned into the TA-cloning vector pGEM-tEasy (Promega). Plasmid DNA template was generated using the TempliPhi system (GE Healthcare Biosciences) and directly sequenced. We identified an identical 1-bp deletion of A in shotgun clones derived from four independent PCR fragments. To confirm the mutation and determine the full sequence of Flg from the mutant strain, we constructed a BAC library from homozygous ft/ft mice, which was screened by hybridization, and the resultant hits were confirmed by PCR (Amplicon Express). From a BAC containing the entire locus, we subcloned exon 3 into a plasmid vector by recombineering (Red/ET system, Gene Bridges). The subclone was subjected to random transposon insertion using the EZ-Tn5 oKAN-24 insertion kit (EPICENTRE Biotechnologies), and 96 transposon insertion clones were sequenced bidirectionally from the Tn5 insertion site, allowing full assembly of exon 3 with Bninefold oversequencing. Genotyping. For allele-specific PCR detection of the ft mutation, we amplified genomic DNA (2 ng) with primers mFlgdelA-F and mFlgdelA-R (Supplementary (Fig. 2d) . To more conveniently genotype animals, we developed a PCR assay to detect a 15-bp insertion polymorphism at the 5¢ end of exon 3 in linkage disequilibrium with the ft mutation. This insertion creates an AccI restriction site. We used primers FTins15.F and FTins15.R ( Supplementary  Table 3 ) in standard PCR reactions using the following amplification conditions: (94 1C, 5 min) Â1; (94 1C, 30 s; 58 1C, 30 s; 72 1C, 1 min) Â35; (72 1C, 5 min) Â1. Five microliters of PCR product were digested overnight with 2.5 U AccI and resolved on 1.5% agarose gels. The 678-bp C57BL/6 allele does not digest; the ft allele digests to yield fragments of 559 bp and 134 bp ( Fig. 2e ).
C-terminal antibody. The C-terminal antibody specific for mouse profilaggrin was generated against the amino-acid sequence ESIFTAKHLDFNQSHS. The peptide was conjugated to KLH via an N-terminal cysteine residue before injection into New Zealand white rabbits (Genemed Synthesis). The serum was affinity purified before use. Urea/Tris extracts were prepared from newborn homozygous ft/ft mice and control C57BL/6 mice as described 11 . Protein samples were separated on 5-12% SDS/polyacrylamide gels and transferred to PVDF membrane (Millipore). Blots were probed with C-terminal antibody and immunoreactive proteins visualized with ECL (Amersham/GE Healthcare Cutaneous challenge with OVA. We challenged the intact skin of wt/wt, wt/ft and ft/ft mice with OVA (Sigma Chemicals) by cutaneous exposure. We applied OVA in a regimen involving three cycles of daily exposure to OVA for 5 consecutive days (see Supplementary Fig. 1a ). Abdominal hair was carefully shaved 24 h before application of OVA; mice with any visual damage to the skin were not used. OVA (fraction V; Sigma) was prepared in PBS (Dulbecco's PBS; Sigma) at 1 mg/ml. Mice were restrained and 50 ml of OVA solution, or 50 ml of PBS, was applied to the shaved skin and allowed to air dry. To address systemic allergen treatment, we challenged wt/wt and ft/ft mice with OVA in alum as an adjuvant by intraperitoneal injection as described 30 (see Supplementary Fig. 3b ).
Measurement of trans-epidermal water loss (TEWL). We used a Courage and Khazaka Tewameter TM210 (Enviroderm) to measure TEWL. TEWL analysis of the abdomen of male and female adult (6-10 weeks of age) wt/wt and ft/ft mice occurred 24 h after shaving. Any mice with visual damage to the skin following shaving were not included in the analysis. TEWL was recorded at ambient temperature 19-21 1C and humidity 50% ± 5. In mice sensitized to OVA, TEWL was measured in PBS-and OVA-treated mice after OVA application.
Spleen cell preparation. Single-cell suspensions were prepared from spleens. Spleen cells were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% (v/v) heat-inactivated FCS (FCS; Labtech), 2 mM L-glutamine (Gibco), 50 U/ml penicillin and 50 mg/ml streptomycin (Gibco). Spleen cells were plated at 5 Â 10 6 cells/ml. OVA was subjected to endotoxin removal for use in cell assays as described 30 . Cells were unstimulated (media) or stimulated with OVA (250 and 500 mg/ml) in a 24-well plate (Greiner Bio-One) at 37 1C for 72 h. Supernatants were harvested after 72 h and cytokine levels (IL-4, IL-5, IL-13, IFN-g, IL-10 and IL-17) were measured by ELISA. For cell proliferation analysis, cells were exposed to a range of concentrations of OVA Antibody and cytokine ELISA. Serum OVA-specific IgG, IgG1 and IgG2a levels were detected by direct ELISA using serial dilutions of sera. OVA-specific IgE was measured using biotinylated-OVA with 1:10 sera dilutions. Total serum IgE was measured using PharMingen antibodies (BD Biosciences), according to the manufacturer's instructions. We detected total serum IgG using commercial capture antibodies and IgG standard (Zymed Laboratories; Sigma). Sandwich ELISAs were done to quantify levels of specific cytokines in the supernatants cell cultures (IL-4, IL-5 and IL-13, assays supplied by PharMingen; IL-10, IL-17 and IFN-g, assays supplied by R&D Systems).
Histology. Abdominal skin of age-and sex-matched mice (wt/wt, wt/ft and ft/ft) that were untreated or exposed to OVA was removed and fixed in 10% formaldehyde saline. Paraffin sections were stained with hematoxylin and eosin. Tissue sections were analyzed with slides blinded to genotype and exposure to allergen. To quantify the individual inflammatory cells infiltrating the skin, we used a previous described scoring system 20 . We counted the total number of cells, lymphocytes, eosinophils and mononuclear cells per Â1,000 high-power fields (HPF) of view, with 15-20 HPFs scored per mouse. Lungs were processed for histopathological analysis as described 30 .
OVA challenge regimen for airway hyper-responsiveness (AHR). wt/wt and ft/ft mice were exposed to OVA cutaneously or intraperitoneally and then exposed to 20 min of continuous aerosol of 1% OVA each day for five consecutive days (as shown in Supplementary Figs. 1b and 3a, respectively) . Epicutaneous exposure to OVA was achieved by repeated tape-stripping of shaved skin 25 before OVA application using the regimen in Supplementary  Figure 1b . AHR was analyzed the day following the final aerosol challenge. Mice were anesthetized, tracheostomized and ventilated. AHR was measured using a whole-body plethysmograph with a pneumotachograph linked to a transducer (EMMS). The average lung resistence (R L ) and the area under the resistence curve (R L AUC) parameters were quantified for 3-min periods at baseline and after exposure to nebulized endotoxin-free PBS (Sigma) and acetyl-b-methycholine chloride (Sigma) at 10, 30, 60 and 120 mg/ml. Bronchoalveolar lavage (BAL) fluids were collected by canulating the trachea and lavaging the lungs with a 1.0 ml of ice-cold PBS. BAL cells were pelleted, washed and counted. The numbers of eosinophils in BAL were analyzed by flow cytometry as described 30 . Lungs were removed from mice for histology.
Statistics. All animal experiments were repeated at least twice. GraphPad Prism and GraphPad Instat software were used for data analysis. Difference between groups was determined by Student's t-test or, if nonparametric, Welch corrected t-test. Differences were considered significant when P o 0.05.
Accession codes. BAC clone RP23-227A12, AC158361; 5¢ Flg, AF510860; 3¢ Flg, J03458; Flg complete sequence from ft mouse strain, FJ824603.
Note: Supplementary information is available on the Nature Genetics website.
